cyclin D1蛋白表达与卵巢浆液性肿瘤预后的关系

目的 :探讨cyclinD1蛋白表达与卵巢浆液性肿瘤患者预后的关系。方法 :采用免疫组化SP法检测 91例卵巢浆液性肿瘤和 2 4例有癌转移的淋巴结中cyclinD1蛋白表达 ,并以 10例正常卵巢组织作对照。结果 :正常卵巢组织、良性浆液性卵巢肿瘤、交界性瘤、浆液性卵巢腺癌和转移性卵巢腺癌癌细胞的cyclinD1蛋白表达阳性率分别为 0、10 .0 %、53.3 %、83.9%和 83.3%。交界性瘤、浆液性卵巢腺癌和有癌转移的淋巴结组织中cyclinD1蛋白表达阳性率显著高于正常卵巢组织和良性浆液性卵巢肿瘤。cyclinD1蛋白表达阳性的浆液性卵巢腺癌患者预后较好 ,但并非卵巢浆液性囊腺癌患者独立的预后因素。结论 :cyclinD1癌基因在卵巢浆液性恶性肿瘤的发生过程中起重要作用。cyclinD1蛋白过表达可能是浆液性卵巢癌患者预后良好的指标 ,但并非影响预后的独立因素

Relationship between expression of cyclin D1 and prognosis of serous ovarian tumour

Objective:To determine the relationship between expressions of cyclin D1 and pro gnoses of patients with serous ovarian tumour.Methods:The expression of cyclin D1 protein in ovarian serous tumour sections from 20 patients with benign tumour,15 patients with borderline tumour,56 patients with invasive tumour,and in lymphoid node sections from 24 patients with lymphoid node metastasis,were analysed using immunohistochemistry, and compared with 10 normal ovarian tissue samples. The tumours that overexpressed cyclin D1 in more than 10% of neoplastic cells were considered positive. Results: The overexpressions of cyclin D1 were observed in 0,10.0%,53.3%,83.9%,and 83.3% of normal ovarian tissue, benign, borderline, invasive tumour,and lymphoid node samples respectively. The overexpression rates of cycliin D1 were significant higher in borderline,invasive tumour,and lymphoid node samples than those in normal ovarian tissues and benign tumours(P<0.001).The prognoses of the patients with ovarian invasive tumour overexpressed cyclin D1 were better (P=0.0038),but there was no association between protein overexpression and tumours stage and differentiation.The overexpression of cyclin D1 was not a independent prognostic factor of the patients with ovarian invasive tumour(P=0.303). Conclusions:The overexpression of cyclin D1 gene should play an important role in oncogenesis of ovarian serous tumour. The overexpression of cyclin D1 could be a marker of good prognosis,but not an independent prognostic factor of the patients with ovarian invasive tumours.